API | sacituzumab govitecan

sacituzumab govitecan (Trodelvy) Report issue

Biologics mAb ADC Approved ^FDA First in Class Fast Track ^FDA Breakthrough Therapy ^FDA Accelerated Approval ^FDA

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

sacituzumab govitecan

sacituzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA topoisomerase 1 (Homo sapiens) ^UniProt
- Tumor-associated calcium signal transducer 2 (Homo sapiens) ^UniProt
- Tumor-associated calcium signal transducer 2 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: SN-38
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$1530.8000 - $2002.3900

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

immu-132 | sacituzumab govitecan

Organizations (49)

Research & Development (49)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (29)

Approved Indications (2)

Breast Neoplasms (approved 2020)

Triple Negative Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (29)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Cholangiocarcinoma (Phase 2)

Drugs, Investigational (Phase 3)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Liver Failure (Phase 1)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Salivary Gland Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 63
# of Trial Organizations: 49

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue